Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 11201 | Palmetto GBA | A and B and HHH MAC | SC |
| 11301 | Palmetto GBA | A and B and HHH MAC | VA |
| 11401 | Palmetto GBA | A and B and HHH MAC | WV |
| 11501 | Palmetto GBA | A and B and HHH MAC | NC |
| 11202 | Palmetto GBA | A and B and HHH MAC | SC |
| 11302 | Palmetto GBA | A and B and HHH MAC | VA |
| 11402 | Palmetto GBA | A and B and HHH MAC | WV |
| 11502 | Palmetto GBA | A and B and HHH MAC | NC |
| 10111 | Palmetto GBA | A and B MAC | AL |
| 10211 | Palmetto GBA | A and B MAC | GA |
| 10311 | Palmetto GBA | A and B MAC | TN |
| 10112 | Palmetto GBA | A and B MAC | AL |
| 10212 | Palmetto GBA | A and B MAC | GA |
| 10312 | Palmetto GBA | A and B MAC | TN |
Billing and coding articles A54768 and A56476: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A54768 (Billing and Coding: Cardiac Blood Pool Imaging (Multiple Gated Acquisition Scanning- MUGA, Ventriculography) When Performed in Conjunction with Cardiotoxic Chemotherapy), Billing and Coding A56476 (Billing and Coding: Cardiac Radionuclide Imaging) carry the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.
A54768: Billing and Coding: Cardiac Blood Pool Imaging (Multiple Gated Acquisition Scanning- MUGA, Ventriculography) When Performed in Conjunction with Cardiotoxic Chemotherapy (Billing and Coding, effective 2025-10-01)
- Covered ICD-10-CM codes
- 1182
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 11
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| C00.0 | Malignant neoplasm of external upper lip |
| C00.1 | Malignant neoplasm of external lower lip |
| C00.3 | Malignant neoplasm of upper lip, inner aspect |
| C00.4 | Malignant neoplasm of lower lip, inner aspect |
| C00.6 | Malignant neoplasm of commissure of lip, unspecified |
| C00.8 | Malignant neoplasm of overlapping sites of lip |
| C00.9 | Malignant neoplasm of lip, unspecified |
| C01 | Malignant neoplasm of base of tongue |
| C02.0 | Malignant neoplasm of dorsal surface of tongue |
| C02.1 | Malignant neoplasm of border of tongue |
| C02.2 | Malignant neoplasm of ventral surface of tongue |
| C02.3 | Malignant neoplasm of anterior two-thirds of tongue, part unspecified |
| C02.4 | Malignant neoplasm of lingual tonsil |
| C02.8 | Malignant neoplasm of overlapping sites of tongue |
| C02.9 | Malignant neoplasm of tongue, unspecified |
| C03.0 | Malignant neoplasm of upper gum |
| C03.1 | Malignant neoplasm of lower gum |
| C04.0 | Malignant neoplasm of anterior floor of mouth |
| C04.1 | Malignant neoplasm of lateral floor of mouth |
| C04.8 | Malignant neoplasm of overlapping sites of floor of mouth |
| C04.9 | Malignant neoplasm of floor of mouth, unspecified |
| C05.0 | Malignant neoplasm of hard palate |
| C05.1 | Malignant neoplasm of soft palate |
| C05.2 | Malignant neoplasm of uvula |
Procedure codes: 78472, 78473, 78481, 78483, 78494, 78496, J0153 (Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)), J0280 (Injection, aminophyllin, up to 250 mg), J0461 (Injection, atropine sulfate, 0.01 mg), J1245 (Injection, dipyridamole, per 10 mg), J1250 (Injection, dobutamine hydrochloride, per 250 mg).
A56476: Billing and Coding: Cardiac Radionuclide Imaging (Billing and Coding, effective 2026-10-01)
- Covered ICD-10-CM codes
- 632
- 2 groups
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 26
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| A18.84 | Tuberculosis of heart |
| C58 | Malignant neoplasm of placenta |
| C81.10 | Nodular sclerosis Hodgkin lymphoma, unspecified site |
| C81.11 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.12 | Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes |
| C81.13 | Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.14 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.15 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.16 | Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.17 | Nodular sclerosis Hodgkin lymphoma, spleen |
| C81.18 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites |
| C81.19 | Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites |
| C81.20 | Mixed cellularity Hodgkin lymphoma, unspecified site |
| C81.21 | Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck |
| C81.22 | Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes |
| C81.23 | Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes |
| C81.24 | Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C81.25 | Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb |
| C81.26 | Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes |
| C81.27 | Mixed cellularity Hodgkin lymphoma, spleen |
| C81.28 | Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites |
| C81.29 | Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites |
| C81.30 | Lymphocyte depleted Hodgkin lymphoma, unspecified site |
| C81.31 | Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck |
Procedure codes: 78431, 78451, 78452, 78453, 78454, 78472, 78473, 78481, 78483, 78491, 78492, 78494, 78496, A4641 (Radiopharmaceutical, diagnostic, not otherwise classified), A9500 (Technetium tc-99m sestamibi, diagnostic, per study dose), A9501 (Technetium tc-99m teboroxime, diagnostic, per study dose), A9502 (Technetium tc-99m tetrofosmin, diagnostic, per study dose), A9505 (Thallium tl-201 thallous chloride, diagnostic, per millicurie), A9526 (Nitrogen n-13 ammonia, diagnostic, per study dose, up to 40 millicuries), A9555 (Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries), A9611 (Flurpiridaz f 18, diagnostic, 1 millicurie), J0153 (Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)), J0280 (Injection, aminophyllin, up to 250 mg), J0461 (Injection, atropine sulfate, 0.01 mg), J1245 (Injection, dipyridamole, per 10 mg), J1250 (Injection, dobutamine hydrochloride, per 250 mg).
Coverage indications, limitations and medical necessity
The 2 types of radionuclide studies commonly used for cardiac evaluation are myocardial perfusion imaging (MPI) and cardiac blood pool imaging (multiple gated acquisition scanning (MUGA), ventriculography). MPI is used primarily for the evaluation of coronary artery disease (CAD). Ventriculography is sometimes referred to as MUGA or cardiac blood pool imaging and is primarily used to evaluate valvular disease and cardiomyopathies. Either type of study may be obtained at rest or with stress. Stress may be provided by exercise or with pharmacologic agents.
MPI is a diagnostic procedure that evaluates blood flow to cardiac muscle using radionuclides. A gamma camera is used to record images in planar or tomographic (single photon emission computed tomography (SPECT)) projections. Use of dual radiopharmaceuticals permit concurrent studies at rest and after stress, which are then compared and interpreted by a nuclear physician. Since the radiopharmaceutical accumulates in the myocardium in relation to blood flow, ischemic and infarcted myocardium can be detected.
With the use of technetium based radiopharmaceuticals, the perfusion imaging may be linked to acquisition of “first pass” data to visualize blood flow through the right heart, lungs and left heart giving diagnostically useful information about cardiac chamber shunts, wall motion, cardiac output, ejection fraction (EF), left ventricular volume, shunt fraction and valvular regurgitation.
Positron emission tomography (PET) scans performed for the diagnosis and management of patients with known or suspected CAD, using the Food and Drug Administration (FDA) approved Rubidium 82 (Rb 82) , are covered when the following conditions are met:
• The PET scan (at rest or rest with stress) is performed in place of SPECT; or
• Is performed following an inconclusive SPECT (results that are equivocal, technically uninterpretable, or discordant with the patient’s other clinical data).
In such cases, the PET scan must have been determined to be medically necessary to guide further treatment of the patient.
When a PET scan is performed as an additional diagnostic test in the instance of an equivocal SPECT, the reason for performing the PET scan must be clearly documented in the patient’s record.
The following studies are considered investigational and will not be covered:
• Ambulatory radionuclide cardiac monitoring
• Monoclonal anti-myosin imaging
• Radionuclide imaging of thrombi
• Radionuclide imaging of cardiac adrenergic nerves
Myocardial Perfusion Imaging
Patients with a high pretest probability of disease are usually not candidates for this study unless determination of the size and reversibility of a defect are required for clinical decision making. Patients whose diagnosis is in question benefit most from this study. Patients with a low pretest probability of disease are usually not studied except when a prior exercise stress test by treadmill electrocardiogram (ECG) or echocardiogram (echo) is a presumed false positive. Stress MPI, preceded by satisfactory stress echo, is not medically necessary.
Indications for Myocardial Perfusion Imaging
1. Acute myocardial infarction (AMI) - MPI is not typically performed during the acute period of myocardial infarction (MI), if the diagnosis is established by other means. In selected patients, imaging is appropriate in the assessment of:
• Disease severity
• Risk assessment and/or prognosis
• Efficacy of acute reperfusion therapy
• Evidence of myocardial salvage
• Suspected infarction when the combination of history and other tests is not diagnostic
2. Unstable angina - MPI may be useful as an adjunct to other tests in the diagnosis or treatment of unstable angina only when the combination of history and other tests is not diagnostic. In selected patients, imaging is appropriate for:
• Identification of ischemia in the distribution of a known lesion or in remote areas
• Identification of the severity/extent of disease in patients with medically unstable angina or ongoing ischemia
• Measurement of left ventricular function (LVF)
3. Chronic ischemic heart disease - The use of MPI is well established in the diagnosis and management of CAD and is covered in these situations:
• Diagnosis of CAD, especially in patients with atypical chest pain
• Evaluation of abnormal or suspected false positive stress ECG
• Evaluation of other symptoms suspicious for the diagnosis of CAD such as syncope and ventricular arrhythmia
• Assessment of myocardial viability after revascularization or medical management
• Planning percutaneous transluminal coronary angioplasty (PTCA) to identify lesions causing ischemia, if unknown
• Evaluation of suspected or known CAD prior to high risk surgical procedure
• Identification of the presence, location, extent, and severity of myocardial ischemia
• Assessment of drug therapy
• Assessment of symptoms suggesting restenosis following PTCA
• Assessment of symptoms suggesting ischemia following coronary artery bypass graft (CABG)
• Follow up of symptomatic ischemic heart disease
4. Congenital heart disease (CHD) - Echo is the method of choice for evaluating patients with known or suspected CHD. Selected patients may benefit from MPI when assessing for:
• Diagnosis of anomalies of the coronary circulation
• Kawasaki’s disease
5. Post-transplant cardiac disease
• Assessment of coronary arteriopathy
• Evaluation for ventricular dysfunction with post-transplant rejection
Cardiac Blood Pool Imaging (MUGA, Ventriculography)
These services are allowed for the evaluation of ventricular size, wall motion, stroke volume, and EF when this information is medically necessary to direct further evaluation and management of the cardiac condition.
Indications for Cardiac Blood Pool Imaging (MUGA, Ventriculography)
1. Cardiomyopathy - Cardiac blood pool imaging (MUGA, ventriculography) is covered for:
• Diagnosis of hypertrophic cardiomyopathy and/or myocardial ischemia
• Differentiation of ischemic from non-ischemic cardiomyopathy
2. Post-transplant cardiac disease
• Assessment of coronary arteriopathy
• Evaluation for ventricular dysfunction with post-transplant rejection
3. Assessment of cardiac function for cardiotoxic chemotherapy
• A. One baseline study is considered medically necessary prior to the initiation of cardiotoxic chemotherapy when 1 of the following conditions is met:
1. No echo is planned or performed
2. Prior echo is uninterpretable due to poor visualization window
• B. Cardiac function monitoring during or at the completion of cardiotoxic chemotherapy. Cardiotoxic chemotherapy includes any of the following medications:
· 5-FU (5 fluorouracil)
· Adriamycin ® (doxorubicin)
· Avastin ® (bevacizumab)
· Cerubidine ® (daunorubicin)
· Clolar ® (clofarabine)
· Cytoxan ® (cyclophosphamide)
· Epirubicin (Pharmorubicin ® )
· Gleevec ® (imatinib)
· Herceptin ® (trastuzumab)
· Ifex ® (ifosfamide)
· Mutamycin ® (mitomycin)
· Nexavar ® (sorafenib)
· Novantrone ® (mitoxantrone)
· Sutent ® (sunitinib)
· Taxol ® (paclitaxel)
· Taxotere ® (docetaxel)
· Tykerb ® (lapatinib)
· Valstar ® (valrubicin)
· Xeloda ® (capecitabine)
· Zavedos ® (idarubicin)
Pharmacologic Stress Agents
For those patients who are unable to reach 75-100% of their age predicted maximum heart rate by physiologic exercise, vasodilation can be achieved with the use of either dipyridamole or adenosine. Use of pharmacologic agents in MPI is not a standard of care and is not medically necessary unless exercise is not possible. In some cases dobutamine may be used to effect stress through its inotropic effect.
1. Dipyridamole is typically administered intravenously (IV) at 0.57 mg/kg over a 4-minute period. The maximum dose should not exceed 60 mg. Since the dilation effect persists, after injection of the radiopharmaceutical, its effect is typically reversed with IV aminophylline, which must be available to reverse ischemia when it occurs. Dipyridamole is relatively contraindicated in patients with:
• Known bronchospastic lung disease (asthma)
• Systemic hypotension (systolic blood pressure (BP) below 100 mm Hg.)
• AMI less than 48 hours old
• Unstable angina
2. Adenosine is administered IV at 0.14 mg/kg/min over 6 minutes (0.84mg/kg). The vasodilation effect is short lived. Adenosine is contraindicated in patients with:
• Second or third degree atrioventricular (AV) block
• Sinus node disease, except for those with a functioning pacemaker
• Known or suspected bronchoconstrictive or bronchospastic lung disease
• Known hypersensitivity to adenosine
The policy text continues in the CMS record.
Summary of evidence (opening)
N/A
The contractor cites 7 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2015-10-01
- Current revision effective
- 2023-03-23
- Last reviewed by the contractor
- 2023-02-09
- MCD version
- 61
- Derived from
- L31700
The contractor lists 2 National Coverage Determinations as related: NCD 220.12 Single Photon Emission Computed Tomography (SPECT), NCD 220.6.1 PET for Perfusion of the Heart. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L33457 cover?
The 2 types of radionuclide studies commonly used for cardiac evaluation are myocardial perfusion imaging (MPI) and cardiac blood pool imaging (multiple gated acquisition scanning (MUGA), ventriculography). MPI is used primarily for the evaluation of coronary artery disease (CAD). Ventriculography is sometimes referred to as MUGA or cardiac blood pool imaging and is primarily used to evaluate valvular disease… The full 1,270-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L33457 apply to?
Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L33457?
The companion billing and coding article A54768 lists 1,182 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L33457?
A denial under LCD L33457 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A54768's 1,182 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.